How Long Does It Take for Testosterone to Peak After Injection?

Key Takeaways

The Short Answer: Testosterone Peaks at 24–72 Hours

The Endocrine Society Clinical Practice Guideline (Bhasin S et al., JCEM, 2018) documents the pharmacokinetic profile of injectable testosterone esters: after IM injection of testosterone cypionate or enanthate, serum testosterone rises to supraphysiological levels within 24–48 hours, then declines progressively toward sub-therapeutic trough levels before the next dose — producing the characteristic large peak-to-trough ratio of weekly injection protocols. [1]

A 2022 systematic review in JCEM by Figueiredo MG, Gagliano-Jucá T, and Basaria S (Brigham and Women’s Hospital / Harvard) analysed all available pharmacokinetic data on SubQ vs IM testosterone. Both routes produced peak testosterone within 24–72 hours; IM reached peak earlier and at a higher absolute value. The trough phase — the lowest point before the next injection — correlates with return of hypogonadal symptoms in sensitive men, and SubQ administration measurably reduces peak-to-trough amplitude. [2]

Why Levels Rise Gradually — Not Immediately After Injecting

Testosterone cypionate carries an 8-carbon ester at the 17β position. This esterification makes the molecule highly lipophilic (fat-soluble) and depot-forming in tissue. After IM injection, esterase enzymes in blood and tissue slowly cleave the ester bond, releasing free testosterone into the systemic circulation over days. The FDA prescribing information for testosterone cypionate (Hospira) confirms an elimination half-life of approximately 7–8 days for the intramuscular route. [3]

The practical consequence: men who expect to “feel” their injection within minutes or hours are misunderstanding the pharmacology. The clinical effects of testosterone — improved energy, libido, mood — build over Days 1–4 as levels rise and then remain elevated, not within the first hour of injection. Any immediate perceived effect on injection day is almost certainly a placebo response.

Day-by-Day Timeline: What Happens to Your Testosterone Levels

Based on published pharmacokinetic data for testosterone cypionate 100–200 mg/week weekly IM injection (the most common US TRT protocol):

The wide peak-to-trough variation of weekly IM injections is documented in a 2022 pharmacokinetic review by Pastuszak et al. (Andrology) — which found that TE and TC produce supraphysiological levels shortly after injection, decreasing to sub-therapeutic levels in between dosing intervals, resulting in large total testosterone peak-to-trough ratios. [4]

Subcutaneous vs. Intramuscular: A Better Pharmacokinetic Profile

Subcutaneous testosterone has emerged as the preferred route for many TRT patients. Figueiredo et al. (JCEM, 2022) reviewed all available pharmacokinetic and clinical data on SubQ testosterone and concluded: SubQ injections produce smaller peak-to-trough fluctuations than IM, more closely mimicking endogenous secretion, and may reduce adverse effects associated with supraphysiological peaks — including erythrocytosis and elevated estradiol. Choi et al. (J Urology, 2022) directly compared IM testosterone cypionate vs. SubQ testosterone enanthate autoinjector in hypogonadal men, finding the SubQ group had significantly lower rates of elevated hematocrit, PSA, and estradiol — attributable to the lower peak-to-trough amplitude. The FDA-approved Xyosted (75 mg/week SubQ) achieved mean trough concentrations of 487 ng/dL at 52 weeks with minimal fluctuation. [2][5]

For patients experiencing significant peak-related side effects — elevated estradiol, mood swings, breast tenderness, or erythrocytosis — switching from IM to SubQ is frequently the appropriate clinical intervention before considering dose reduction. Learn more about injection routes and technique in our testosterone therapy program.

2025–2026: The Evolving Regulatory Landscape for Testosterone Therapy

In February 2025, the FDA issued a landmark labeling update for all testosterone products: the cardiovascular black-box warning was removed, based primarily on data from the TRAVERSE trial (Lincoff AM, Bhasin S, et al., NEJM, 2023). TRAVERSE enrolled 5,246 hypogonadal men aged 45–80 with pre-existing or high cardiovascular risk — and found testosterone non-inferior to placebo for major adverse cardiovascular events (MACE: 7.0% vs. 7.3%; HR 0.96; P < .001 for noninferiority). This was the largest randomized testosterone cardiovascular safety trial ever conducted. [6][7]

When to Draw Your Lab Work: The Trough Rule

The AUA 2022 Testosterone Deficiency Guideline specifies that testosterone should be monitored at trough — immediately before the next scheduled injection — after steady state has been achieved (approximately 4–6 weeks after initiating therapy or changing dose). For testosterone cypionate with a half-life of ~8 days, steady state is reached at approximately 5 half-lives: ~40 days. [8]

For the complete AUA-recommended monitoring schedule — including hematocrit thresholds, PSA rules, estradiol timing, and target value ranges — see our evidence-based TRT dosing and monitoring guide.

Real-World Evidence: What 9,000+ TRT Patients Show

A 2026 open-access retrospective cohort study in the World Journal of Men’s Health (accepted September 2025, published April 2026) analyzed over 9,000 men treated for testosterone deficiency between 2019 and 2024 in a real-world UK clinical setting. Findings confirmed the clinical patterns established in controlled trials: meaningful symptom improvement at therapeutic trough levels, with the most significant predictors of optimal response being injection frequency (twice-weekly outperforming weekly for symptom stability) and achievement of mid-normal trough testosterone concentrations. [9]